Allergic conditions; rheumatic arthritis; nephrotic syndrome; collagen diseases; fulminating SLE; bronchial asthma; status asthmaticus; severe chronic bronchial asthma; chronic ulcerative colitis; thrombocytopenia; organ transplant; shock [cardiogenic / traumatic].
0.5-5mg daily. 1.M injection or slow 1.V inj or infusion. 4-20mg up to QID. Children up to 1 year; 1mg. 1-5 years; 2mg. 6-12 years; 4mg up to QID.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA [mRNA]. Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids.
Betamethasone may suppress transcription of mRNA in some cells like lymphocytes.
Patient monitor if used for prolonged use; use the lowest possible dose; use with caution in patients suffering from diabetes mellitus; CCF; hypertension; infections; thrombo-embolism; elderly; ureamia; and chronic renal failure.
Hypersensitivity to the drug; systemic fungal infections; live virus vaccination; IM use in idiopathic thrombocytopenic purpura; peptic ulceration; psychosis; osteoporosis; severe psychoneurosis; TB; ocular herpes simplex; primary glaucoma
Hypertension; hypersensitivity reactions; muscle mass loss; osteoporosis; throm-bo-embolism; thrombophlebitis; cardiac arrhyth-mias; insomnia; fatigue; hyperglyceamia; glau-coma; cushoid states; steroid psychosis and aggravation of pre-existing psychiatric condi-tions; syncopal episodes; GI disorders; impaired wound healing; thin fragile skin; acne; hirsutism; increased appetite and weight gain; convulsions; pancreatitis; spontaneous fractures; increased susceptibility to infections; peptic ulceration; myopathy; growth retardation in children; adrenal insufficiency; increased blood coagulability; masking of infections; skin pigmentation; immunosuppression.
Drug interactions: Drugs that may be affected by the glucocorticoids: anticoagulants; diuretics; salicylates; digitalis; anticholinesterases; cyclosporine; and isoniazid. Drugs that may affect glucocorticoids; Oral contraceptives; rifampicin; macrolide antibiotics; ketoconazole; barbiturates; ephedrine